PFE
Price
$23.39
Change
+$0.04 (+0.17%)
Updated
Jun 4 closing price
Capitalization
157.14B
61 days until earnings call
SNY
Price
$49.50
Change
+$0.31 (+0.63%)
Updated
Jun 4 closing price
Capitalization
122.61B
56 days until earnings call
Interact to see
Advertisement

PFE vs SNY

Header iconPFE vs SNY Comparison
Open Charts PFE vs SNYBanner chart's image
Pfizer
Price$23.39
Change+$0.04 (+0.17%)
Volume$24.5M
Capitalization157.14B
Sanofi ADS
Price$49.50
Change+$0.31 (+0.63%)
Volume$1.39M
Capitalization122.61B
PFE vs SNY Comparison Chart
Loading...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PFE vs. SNY commentary
Jun 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PFE is a Hold and SNY is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 05, 2025
Stock price -- (PFE: $23.39 vs. SNY: $49.50)
Brand notoriety: PFE: Notable vs. SNY: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: PFE: 49% vs. SNY: 50%
Market capitalization -- PFE: $157.14B vs. SNY: $122.61B
PFE [@Pharmaceuticals: Major] is valued at $157.14B. SNY’s [@Pharmaceuticals: Major] market capitalization is $122.61B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PFE’s FA Score shows that 1 FA rating(s) are green whileSNY’s FA Score has 1 green FA rating(s).

  • PFE’s FA Score: 1 green, 4 red.
  • SNY’s FA Score: 1 green, 4 red.
According to our system of comparison, SNY is a better buy in the long-term than PFE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PFE’s TA Score shows that 3 TA indicator(s) are bullish while SNY’s TA Score has 3 bullish TA indicator(s).

  • PFE’s TA Score: 3 bullish, 4 bearish.
  • SNY’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, SNY is a better buy in the short-term than PFE.

Price Growth

PFE (@Pharmaceuticals: Major) experienced а +0.91% price change this week, while SNY (@Pharmaceuticals: Major) price change was -4.79% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.27%. For the same industry, the average monthly price growth was +2.61%, and the average quarterly price growth was +3.54%.

Reported Earning Dates

PFE is expected to report earnings on Aug 05, 2025.

SNY is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+3.27% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PFE($157B) has a higher market cap than SNY($123B). PFE has higher P/E ratio than SNY: PFE (74.92) vs SNY (20.80). SNY YTD gains are higher at: 7.181 vs. PFE (-8.668). SNY has higher annual earnings (EBITDA): 12.6B vs. PFE (9.56B). PFE has more cash in the bank: 12.7B vs. SNY (8.98B). SNY has less debt than PFE: SNY (18.4B) vs PFE (70.8B). PFE has higher revenues than SNY: PFE (58.5B) vs SNY (46.4B).
PFESNYPFE / SNY
Capitalization157B123B128%
EBITDA9.56B12.6B76%
Gain YTD-8.6687.181-121%
P/E Ratio74.9220.80360%
Revenue58.5B46.4B126%
Total Cash12.7B8.98B141%
Total Debt70.8B18.4B385%
FUNDAMENTALS RATINGS
PFE vs SNY: Fundamental Ratings
PFE
SNY
OUTLOOK RATING
1..100
95
VALUATION
overvalued / fair valued / undervalued
1..100
3
Undervalued
7
Undervalued
PROFIT vs RISK RATING
1..100
10056
SMR RATING
1..100
7474
PRICE GROWTH RATING
1..100
6161
P/E GROWTH RATING
1..100
9686
SEASONALITY SCORE
1..100
350

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PFE's Valuation (3) in the Pharmaceuticals Major industry is in the same range as SNY (7). This means that PFE’s stock grew similarly to SNY’s over the last 12 months.

SNY's Profit vs Risk Rating (56) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (100). This means that SNY’s stock grew somewhat faster than PFE’s over the last 12 months.

SNY's SMR Rating (74) in the Pharmaceuticals Major industry is in the same range as PFE (74). This means that SNY’s stock grew similarly to PFE’s over the last 12 months.

SNY's Price Growth Rating (61) in the Pharmaceuticals Major industry is in the same range as PFE (61). This means that SNY’s stock grew similarly to PFE’s over the last 12 months.

SNY's P/E Growth Rating (86) in the Pharmaceuticals Major industry is in the same range as PFE (96). This means that SNY’s stock grew similarly to PFE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PFESNY
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
62%
Bullish Trend 1 day ago
53%
Momentum
ODDS (%)
Bearish Trend 1 day ago
60%
Bearish Trend 1 day ago
51%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
51%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
57%
Bearish Trend 1 day ago
49%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
58%
Bearish Trend 1 day ago
41%
Advances
ODDS (%)
Bullish Trend 6 days ago
56%
Bullish Trend 15 days ago
53%
Declines
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 3 days ago
50%
BollingerBands
ODDS (%)
Bearish Trend 6 days ago
60%
Bearish Trend 3 days ago
40%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
47%
View a ticker or compare two or three
Interact to see
Advertisement
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GROY1.940.05
+2.65%
Gold Royalty Corp
KALA4.120.03
+0.73%
Kala BIO
PPG111.930.56
+0.50%
PPG Industries
HCI165.450.40
+0.24%
HCI Group
SPR37.79-0.40
-1.05%
Spirit Aerosystems Holdings

SNY and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNY has been loosely correlated with SNYNF. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then SNYNF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNY
1D Price
Change %
SNY100%
+0.63%
SNYNF - SNY
61%
Loosely correlated
+0.32%
GSK - SNY
47%
Loosely correlated
+0.84%
PFE - SNY
45%
Loosely correlated
+0.17%
NVS - SNY
45%
Loosely correlated
+0.86%
AZN - SNY
44%
Loosely correlated
+1.64%
More